Participants
This study was approved by the Fred Hutchinson Cancer Research Center (FHCRC) Institutional Review Board. FHCRC maintains continuous follow-up of HCT survivors who consent to long-term follow-up via an annual patient-reported health survey, with the earliest transplant performed in 1971.17,18 Patients underwent HCT for both malignant and non-malignant conditions, including immunodeficiencies and benign hematologic disorders. The following HCT survivors were eligible for this study: alive ≥1 year after HCT at FHCRC, age <21 years at time of transplant, current age ≥18 years at the time of survey, and available current mailing address. Baseline demographic characteristics (including age, sex, race and ethnicity, underlying diagnosis) and HCT details (including conditioning regimen, donor type, chronic graft versus host disease (cGVHD) status) were retrieved from the FHCRC research database. Additionally, pre-HCT cranial irradiation exposure was abstracted from the medical record.